Over the recent years we’ve witnessed the implementation of the so-called “epigenetic drugs” in the management of several cancer types. Among the epigenetic pharmacopeia, several histone deacetylase inhibitors (HDACI) have recently received FDA-approval for treating certain T-cell lymphoma subtypes. Yet, their relatively low efficacy in B-cell lymphoma patients demands a better understanding of their biological effects.
In light of this unresolved clinical need, our lab in...
